Immunological reaction in TNF-α-mediated osteoclast formation and bone resorption in vitro and in vivo

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Kitaura, Hideki ^a   Kimura, Keisuke ^a   Ishida, Masahiko ^a   Kohara, Haruka ^b   Yoshimatsu, Masako ^b   Takano Yamamoto, Teruko ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; FAS LIGAND; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN C FOS; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; TNFSF11 PROTEIN, HUMAN;

ANTIBODY PRODUCTION; BONE METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ANIMAL; BONE; DRUG EFFECT; GENE EXPRESSION; GENETICS; IMMUNOLOGY; OSTEOBLAST; OSTEOCLAST; PATHOLOGY; STROMA CELL; T LYMPHOCYTE; DRUG EFFECTS;

ANIMALS; ARTHRITIS, RHEUMATOID; BONE AND BONES; BONE RESORPTION; GENE EXPRESSION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-18; OSTEOBLASTS; OSTEOCLASTS; RANK LIGAND; STROMAL CELLS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878636899     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/181849     Document Type: Review

References (83)

1. Tracey K. J., Cerami A., Tumor necrosis factor, other cytokines and disease. Annual Review of Cell Biology 1993 9 317 343 2-s2.0-0027333425
2. Wong M., Ziring D., Korin Y., Desai S., Kim S., Lin J., Gjertson D., Braun J., Reed E., Singh R. R., TNF α blockade in human diseases: mechanisms and future directions. Clinical Immunology 2008 126 2 121 136 2-s2.0-37849052961 10.1016/j.clim.2007.08.013
3. Teitelbaum S. L., Bone resorption by osteoclasts. Science 2000 289 5484 1504 1508 2-s2.0-0034284970 10.1126/science.289.5484.1504
4. Scott D. L., Pugner K., Kaarela K., Doyle D. V., Woolf A., Holmes J., Hieke K., The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000 39 2 122 132 2-s2.0-0034104307 (Pubitemid 30139344)
5. Burke-Gaffney A., Keenan A. K., Does TNF- α directly increase endothelial cell monolayer permeability? Agents and Actions 1993 38 C83 C85 2-s2.0-0027460077 (Pubitemid 23117998)
6. Lu X., Gilbert L., He X., Rubin J., Nanes M. S., Transcriptional regulation of the osterix (Osx, Sp7) promoter by tumor necrosis factor identifies disparate effects of mitogen-activated protein kinase and NF B pathways. Journal of Biological Chemistry 2006 281 10 6297 6306 2-s2.0-33646588049 10.1074/jbc.M507804200 (Pubitemid 43847561)
7. Lehmann W., Edgar C. M., Wang K., Cho T. J., Barnes G. L., Kakar S., Graves D. T., Rueger J. M., Gerstenfeld L. C., Einhorn T. A., Tumor necrosis factor alpha (TNF- α) coordinately regulates the expression of specific matrix metalloproteinases (MMPS) and angiogenic factors during fracture healing. Bone 2005 36 2 300 310 2-s2.0-20044375180 10.1016/j.bone.2004.10.010 (Pubitemid 40283587)
8. Geiler J., Buch M., McDermott M. F., Anti-TNF treatment in rheumatoid arthritis. Current Pharmaceutical Design 2011 17 29 3141 3154 10.2174/138161211798157658
9. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S. I., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T., Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proceedings of the National Academy of Sciences of the United States of America 1998 95 7 3597 3602 2-s2.0-0032584208
10. Lacey D. L., Timms E., Tan H. L., Kelley M. J., Dunstan C. R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y. X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W. J., Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 93 2 165 176 2-s2.0-0032540319 10.1016/S0092-8674(00)81569-X (Pubitemid 28180851)
11. Ross F. P., Teitelbaum S. L., α v β 3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunological Reviews 2005 208 88 105 2-s2.0-28544443670 (Pubitemid 41746387)
12. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Morinaga T., Higashio K., Martin T. J., Suda T., Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. Journal of Experimental Medicine 2000 191 2 275 286 2-s2.0-0034677177 10.1084/jem.191.2.275 (Pubitemid 30060917)
13. Azuma Y., Kaji K., Katogi R., Takeshita S., Kudo A., Tumor necrosis factor- α induces differentiation of and bone resorption by osteoclasts. Journal of Biological Chemistry 2000 275 7 4858 4864 2-s2.0-0034681337 10.1074/jbc.275.7.4858 (Pubitemid 30108878)
14. Lam J., Takeshita S., Barker J. E., Kanagawa O., Ross F. P., Teitelbaum S. L., TNF- α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. Journal of Clinical Investigation 2000 106 12 1481 1488 2-s2.0-0034523328 (Pubitemid 32038586)
15. Li P., Schwarz E. M., O'Keefe R. J., Ma L., Boyce B. F., Xing L., RANK Signaling is not required for TNF α -mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNF α -mediated inflammatory arthritis. Journal of Bone and Mineral Research 2004 19 2 207 213 2-s2.0-1642526641 10.1359/JBMR.0301233 (Pubitemid 38116734)
16. Kim N., Kadono Y., Takami M., Lee J., Lee S. H., Okada F., Jung H. K., Kobayashi T., Odgren P. R., Nakano H., Yeh W. C., Lee S. K., Lorenzo J. A., Choi Y., Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. Journal of Experimental Medicine 2005 202 5 589 595 2-s2.0-24344433524 10.1084/jem.20050978 (Pubitemid 41248411)
17. Udagawa N., Takahashi N., Akatsu T., Tanaka H., Sasaki T., Nishihara T., Koga T., Martin T. J., Suda T., Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proceedings of the National Academy of Sciences of the United States of America 1990 87 18 7260 7264 2-s2.0-0025049142
18. Kung Y. Y., Felge U., Sarosi I., Bolon B., Taturi A., Morony S., Capparelli C., Li J., Elliott R., McCabe S., Wong T., Campagnuolo G., Moran E., Bogoch E. R., Van G., Nguyen L. T., Ohashi P. S., Lacey D. L., Fish E., Boyle W. J., Penninger J. M., Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999 402 6759 304 309 2-s2.0-0033581952 10.1038/46303 (Pubitemid 129516268)
19. Kitaura H., Sands M. S., Aya K., Zhou P., Hirayama T., Uthgenannt B., Wei S., Takeshita S., Novack D. V., Silva M. J., Abu-Amer Y., Ross F. P., Teitelbaum S. L., Marrow stromal cells and osteoclast precursors differentially contribute to TNF- α -induced osteoclastogenesis in vivo. Journal of Immunology 2004 173 8 4838 4846 2-s2.0-6344293669 (Pubitemid 39387764)
20. Kitaura H., Zhou P., Kim H. J., Novack D. V., Ross F. P., Teitelbaum S. L., M-CSF mediates TNF-induced inflammatory osteolysis. Journal of Clinical Investigation 2005 115 12 3418 3427 2-s2.0-31044436261 10.1172/JCI26132 (Pubitemid 43121830)
21. Takayanagi H., Kim S., Taniguchi T., Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Research 2002 4 supplement 3 S227 S232 10.1186/ar581
22. Naito A., Azuma S., Tanaka S., Miyazaki T., Takaki S., Takatsu K., Nakao K., Nakamura K., Katsuki M., Yamamoto T., Inoue J. I., Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes to Cells 1999 4 6 353 362 2-s2.0-6544270833 10.1046/j.1365-2443.1999.00265.x (Pubitemid 29359450)
23. Lomaga M. A., Yeh W. C., Sarosi I., Duncan G. S., Furlonger C., Ho A., Morony S., Capparelli C., Van G., Kaufman S., Van Der Heiden A., Itie A., Wakeham A., Khoo W., Sasaki T., Cao Z., Penninger J. M., Paige C. J., Lacey D. L., Dunstan C. R., Boyle W. J., Goeddel D. V., Mak T. W., TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes and Development 1999 13 8 1015 1024 2-s2.0-0033561039 (Pubitemid 29200984)
24. Teitelbaum S. L., Ross F. P., Genetic regulation of osteoclast development and function. Nature Reviews Genetics 2003 4 8 638 649 2-s2.0-0043267732 10.1038/nrg1122 (Pubitemid 36917505)
25. Iotsova V., Caamaño J., Loy J., Yang Y., Lewin A., Bravo R., Osteopetrosis in mice lacking NF- B1 and NF- B2. Nature Medicine 1997 3 11 1285 1289 2-s2.0-0030715563
26. Grigoriadis A. E., Wang Z. Q., Cecchini M. G., Hofstetter W., Felix R., Fleisch H. A., Wagner E. F., c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994 266 5184 443 448 2-s2.0-0028173214
27. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., Saiura A., Isobe M., Yokochi T., Inoue J. I., Wagner E. F., Mak T. W., Kodama T., Taniguchi T., Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Developmental Cell 2002 3 6 889 901 2-s2.0-18744366041 10.1016/S1534-5807(02) 00369-6 (Pubitemid 35460788)
28. Negishi-Koga T., Takayanagi H., Ca 2+ -NFATc1 signaling is an essential axis of osteoclast differentiation. Immunological Reviews 2009 231 1 241 256 2-s2.0-70349100754 10.1111/j.1600-065X.2009.00821.x
29. Koga T., Inui M., Inoue K., Kim S., Suematsu A., Kobayashi E., Iwata T., Ohnishi H., Matozaki T., Kodama T., Taniguchi T., Takayanagi H., Takai T., Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004 428 6984 758 763 2-s2.0-11144354330 10.1038/nature02444 (Pubitemid 38508286)
30. Kaji K., Katogi R., Azuma Y., Naito A., Inoue J. I., Kudo A., Tumor necrosis factor α -induced osteoclastogenesis requires tumor necrosis factor receptor-associated factor 6. Journal of Bone and Mineral Research 2001 16 9 1593 1599 2-s2.0-0034873322 (Pubitemid 32786428)
31. Kanazawa K., Kudo A., TRAF2 is essential for TNF- α -induced osteoclastogenesis. Journal of Bone and Mineral Research 2005 20 5 840 847 2-s2.0-17644395610 10.1359/JBMR.041225 (Pubitemid 40571641)
32. Abu-Amer Y., Erdmann J., Alexopoulou L., Kollias G., Patrick Ross F., Teitelbaum S. L., Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. Journal of Biological Chemistry 2000 275 35 27307 27310 2-s2.0-0034282878 10.1074/jbc.M003886200
33. Takeuchi M., Rothe M., Goeddel D. V., Anatomy of TRAF2: distinct domains for nuclear factor- B activation and association with tumor necrosis factor signaling proteins. Journal of Biological Chemistry 1996 271 33 19935 19942 2-s2.0-0029786304 10.1074/jbc.271.33.19935 (Pubitemid 26281739)
34. Chen Z. J., Ubiquitin signalling in the NF-kappaB pathway. Nature Cell Biology 2005 7 8 758 765 10.1038/ncb0805-758 (Pubitemid 41079044)
35. Hayden M. S., Ghosh S., Signaling to NF- B. Genes and Development 2004 18 18 2195 2224 2-s2.0-4444376712 10.1101/gad.1228704 (Pubitemid 39209568)
36. Vallabhapurapu S., Karin M., Regulation and function of NF- B transcription factors in the immune system. Annual Review of Immunology 2009 27 693 733 2-s2.0-67650724069 10.1146/annurev.immunol.021908.132641
37. Abu-Amer Y., Rossl F. P., McHugh K. P., Livolsi A., Peyron J. F., Teitelbaum S. L., Tumor necrosis factor- α activation of nuclear transcription factor- B in marrow macrophages is mediated by c-Src tyrosine phosphorylation of I B α Journal of Biological Chemistry 1998 273 45 29417 29423 2-s2.0-0032491410 10.1074/jbc.273.45.29417 (Pubitemid 28509944)
38. Naito A., Azuma S., Tanaka S., Miyazaki T., Takaki S., Takatsu K., Nakao K., Nakamura K., Katsuki M., Yamamoto T., Inoue J. I., Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes to Cells 1999 4 6 353 362 2-s2.0-6544270833 10.1046/j.1365-2443.1999.00265.x (Pubitemid 29359450)
39. Lomaga M. A., Yeh W. C., Sarosi I., Duncan G. S., Furlonger C., Ho A., Morony S., Capparelli C., Van G., Kaufman S., Van Der Heiden A., Itie A., Wakeham A., Khoo W., Sasaki T., Cao Z., Penninger J. M., Paige C. J., Lacey D. L., Dunstan C. R., Boyle W. J., Goeddel D. V., Mak T. W., TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes and Development 1999 13 8 1015 1024 2-s2.0-0033561039 (Pubitemid 29200984)
40. Gilbert L., He X., Farmer P., Rubin J., Drissi H., Van Wijnen A. J., Lian J. B., Stein G. S., Nanes M. S., Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2 α A) is inhibited by tumor necrosis factor- α Journal of Biological Chemistry 2002 277 4 2695 2701 2-s2.0-0037169482 10.1074/jbc.M106339200 (Pubitemid 34953297)
41. Gilbert L., He X., Farmer P., Boden S., Kozlowski M., Rubin J., Nanes M. S., Inhibition of osteoblast differentiation by tumor necrosis factor- α Endocrinology 2000 141 11 3956 3964 2-s2.0-0033695186
42. Wei S., Kitaura H., Zhou P., Patrick Ross F., Teitelbaum S. L., IL-1 mediates TNF-induced osteoclastogenesis. Journal of Clinical Investigation 2005 115 2 282 290 2-s2.0-14944371405 10.1172/JCI200523394 (Pubitemid 40385470)
43. Schett G., Review: immune cells and mediators of inflammatory arthritis. Autoimmunity 2008 41 3 224 229 2-s2.0-41449106186 10.1080/08916930701694717 (Pubitemid 351454993)
44. Gao Y., Morita I., Maruo N., Kubota T., Murota S., Aso T., Expression of IL-6 receptor and GP130 in mouse bone marrow cells during osteoclast differentiation. Bone 1998 22 5 487 493 2-s2.0-0031980544 10.1016/S8756-3282(98) 00040-4 (Pubitemid 28226862)
45. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., Saito S., Inoue K., Kamatani N., Gillespie M. T., Martin T. J., Suda T., IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. Journal of Clinical Investigation 1999 103 9 1345 1352 2-s2.0-0033134608 (Pubitemid 29218305)
46. Fox S. W., Fuller K., Bayley K. E., Lean J. M., Chambers T. J., TGF- β 1 and IFN- γ direct macrophage activation by TNF- α to osteoclastic or cytocidal phenotype. Journal of Immunology 2000 165 9 4957 4963 2-s2.0-0034327829
47. Wei S., Wang M. W. H., Teitelbaum S. L., Patrick Ross F., Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF- B and mitogen-activated protein kinase signaling. Journal of Biological Chemistry 2002 277 8 6622 6630 2-s2.0-0037155165 10.1074/jbc.M104957200 (Pubitemid 34968463)
48. Kitaura H., Nagata N., Fujimura Y., Hotokezaka H., Tatamiya M., Nakao N., Yoshida N., Nakayama K., Interleukin-4 directly inhibits tumor necrosis factor- α -mediated osteoclast formation in mouse bone marrow macrophages. Immunology Letters 2003 88 3 193 198 2-s2.0-0041508865 10.1016/S0165-2478(03) 00082-8 (Pubitemid 37006334)
49. Fujii T., Kitaura H., Kimura K., Hakami Z. W., Takano-Yamamoto T., IL-4 inhibits TNF-alpha-mediated osteoclast formation by inhibition of RANKL expression in TNF-alpha-activated stromal cells and direct inhibition of TNF-alpha-activated osteoclast precursors via a T-cell-independent mechanism in vivo. Bone 2012 51 4 771 780 10.1016/j.bone.2012.06.024
50. Owens J. M., Gallagher A. C., Chambers T. J., IL-10 modulates formation of osteoclasts in murine hemopoietic cultures. Journal of Immunology 1996 157 2 936 940 2-s2.0-0029944882 (Pubitemid 26231402)
51. Horwood N. J., Elliott J., Martin T. J., Gillespie M. T., IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. Journal of Immunology 2001 166 8 4915 4921 2-s2.0-0035871615 (Pubitemid 32280701)
52. Nagata N., Kitaura H., Yoshida N., Nakayama K., Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN- γ possibly induced from non-T cell population. Bone 2003 33 4 721 732 2-s2.0-0141527491 10.1016/S8756-3282(03)00213-8 (Pubitemid 37222399)
53. Kitaura H., Nagata N., Fujimura Y., Hotokezaka H., Yoshida N., Nakayama K., Effect of IL-12 on TNF- α -mediated osteoclast formation in bone marrow cells: apoptosis mediated by Fas/Fas ligand interaction. Journal of Immunology 2002 169 9 4732 4738 2-s2.0-0036838565 (Pubitemid 35217134)
54. Yoshimatsu M., Kitaura H., Fujimura Y., Eguchi T., Kohara H., Morita Y., Yoshida N., IL-12 inhibits TNF- α induced osteoclastogenesis via a T cell-independent mechanism in vivo. Bone 2009 45 5 1010 1016 2-s2.0-70349279876 10.1016/j.bone.2009.07.079
55. Onoe Y., Miyaura C., Kaminakayashiki T., Nagai Y., Noguchi K., Chen Q. R., Seo H., Ohta H., Nozawa S., Kudo I., Suda T., IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. Journal of Immunology 1996 156 2 758 764 2-s2.0-0030033449
56. Udagawa N., Horwood N. J., Elliott J., Mackay A., Owens J., Okamura H., Kurimoto M., Chambers T. J., Martin T. J., Gillespie M. T., Interleukin-18 (interferon- γ -inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon- γ to inhibit osteoclast formation. Journal of Experimental Medicine 1997 185 6 1005 1012 2-s2.0-17544389276 10.1084/jem.185.6.1005 (Pubitemid 27136793)
57. Kitaura H., Tatamiya M., Nagata N., Fujimura Y., Eguchi T., Yoshida N., Nakayama K., IL-18 induces apoptosis of adherent bone marrow cells in TNF- α mediated osteoclast formation in synergy with IL-12. Immunology Letters 2006 107 1 22 31 2-s2.0-33748334306 10.1016/j.imlet.2006.06.005 (Pubitemid 44332544)
58. Morita Y., Kitaura H., Yoshimatsu M., Fujimura Y., Kohara H., Eguchi T., Yoshida N., IL-18 inhibits TNF- α -induced osteoclastogenesis possibly via a T cell-independent mechanism in synergy with IL-12 in vivo. Calcified Tissue International 2010 86 3 242 248 2-s2.0-77950863280 10.1007/s00223-010-9335-6
59. Kohara H., Kitaura H., Fujimura Y., Yoshimatsu M., Morita Y., Eguchi T., Masuyama R., Yoshida N., IFN- γ directly inhibits TNF- α -induced osteoclastogenesis in vitro and in vivo and induces apoptosis mediated by Fas/Fas ligand interactions. Immunology Letters 2011 137 1-2 53 61 2-s2.0-79954423688 10.1016/j.imlet.2011.02.017
60. Scardapane A., Breda L., Lucantoni M., Chiarelli F., TNF- α polymorphisms in juvenile idiopathic arthritis: which potential clinical implications? International Journal of Rheumatology 2012 2012 16 756291 10.1155/2012/756291
61. Ritchlin C. T., Haas-Smith S. A., Li P., Hicks D. G., Schwarz E. M., Mechanisms of TNF- α-and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. Journal of Clinical Investigation 2003 111 6 821 831 2-s2.0-0037364369 10.1172/JCI200316069 (Pubitemid 37074957)
62. Redlich K., Hayer S., Ricci R., David J. P., Tohidast-Akrad M., Kollias G., Steiner G., Smolen J. S., Wagner E. F., Schett G., Osteoclasts are essential for TNF- α -mediated joint destruction. Journal of Clinical Investigation 2002 110 10 1419 1427 2-s2.0-0036853902 10.1172/JCI200215582 (Pubitemid 35396913)
63. Chen E., Keystone E. C., Fish E. N., Restricted cytokine expression in rheumatoid arthritis. Arthritis and Rheumatism 1993 36 7 901 910 2-s2.0-0027315167 (Pubitemid 23201104)
64. Brennan F. M., Jackson A., Chantry D., Maini R., Feldmann M., Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989 2 8657 244 247 2-s2.0-0024314554 (Pubitemid 19180612)
65. Feldmann M., Brennan F. M., Maini R. N., Rheumatoid arthritis. Cell 1996 85 3 307 310 2-s2.0-0030003058 10.1016/S0092-8674(00)81109-5 (Pubitemid 26160702)
66. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., Kollias G., Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO Journal 1991 10 13 4025 4031 2-s2.0-0026039673 (Pubitemid 21905432)
67. Schett G., Redlich K., Hayer S., Zwerina J., Bolon B., Dunstan C., Görtz B., Schulz A., Bergmeister H., Kollias G., Steiner G., Smolen J. S., Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis and Rheumatism 2003 48 7 2042 2051 2-s2.0-0038342686 10.1002/art.11150 (Pubitemid 36828700)
68. Li P., Schwarz E. M., O'Keefe R. J., Ma L., Looney R. J., Ritchlin C. T., Boyce B. F., Xing L., Systemic tumor necrosis factor α mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor α -transgenic mice. Arthritis and Rheumatism 2004 50 1 265 276 2-s2.0-0347719264 10.1002/art.11419 (Pubitemid 38084312)
69. Yao Z., Li P., Zhang Q., Schwarz E. M., Keng P., Arbini A., Boyce B. F., Xing L., Tumor necrosis factor- α increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. Journal of Biological Chemistry 2006 281 17 11846 11855 2-s2.0-33744955055 10.1074/jbc.M512624200 (Pubitemid 43855445)
70. Lipsky P. E., Van Der Heijde D. M. F. M., Clair S., Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Weisman M., Emery P., Feldmann M., Harriman G. R., Maini R. N., Infliximab and methotrexate in the treatment of rheumatoid arthritis. The New England Journal of Medicine 2000 343 22 1594 1602 2-s2.0-0034735842 10.1056/NEJM200011303432202 (Pubitemid 32162982)
71. Weinblatt M. E., Kremer J. M., Bankhurst A. D., Bulpitt K. J., Fleischmann R. M., Fox R. I., Jackson C. G., Lange M., Burge D. J., A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. The New England Journal of Medicine 1999 340 4 253 259 2-s2.0-0033611472 10.1056/ NEJM199901283400401 (Pubitemid 29063266)
72. Assier E., Semerano L., Duvallet E., Delavalle L., Bernier E., Laborie M., Grouard-Vogel G., Larcier P., Bessis N., Boissier M. C., Modulation of anti-tumor necrosis factor alpha (TNF- α) antibody secretion in mice immunized with TNF- α kinoid. Clinical and Vaccine Immunology 2012 19 5 699 703 10.1128/CVI.05649-11
73. Aoki K., Saito H., Itzstein C., Ishiguro M., Shibata T., Blanque R., Mian A. H., Takahashi M., Suzuki Y., Yoshimatsu M., Yamaguchi A., Deprez P., Mollat P., Murali R., Ohya K., Horne W. C., Baron R., A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. Journal of Clinical Investigation 2006 116 6 1525 1534 2-s2.0-33745199187 10.1172/JCI22513
74. Saito H., Kojima T., Takahashi M., Horne W. C., Baron R., Amagasa T., Ohya K., Aoki K., A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis. Arthritis and Rheumatism 2007 56 4 1164 1174 2-s2.0-34247279368 10.1002/art.22495 (Pubitemid 46608641)
75. Kouskoff V., Korganow A. S., Duchatelle V., Degott C., Benoist C., Mathis D., Organ-specific disease provoked by systemic autoimmunity. Cell 1996 87 5 811 822 2-s2.0-0030606310 10.1016/S0092-8674(00)81989-3 (Pubitemid 26404281)
76. Orcel P., Feuga M., Bielakoff J., De Vernejoul M. C., Local bone injections of LPS and M-CSF increase bone resorption by different pathways in vivo in rats. American Journal of Physiology 1993 264 3 E391 E397 2-s2.0-0027536168 (Pubitemid 23103951)
77. Chung Y. H., Chang E. J., Kim S. J., Kim H. H., Kim H. M., Lee S. B., Ko J. S., Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts. Journal of Periodontal Research 2006 41 4 288 296 2-s2.0-33748544280 10.1111/j.1600-0765.2006.00876.x (Pubitemid 44392298)
78. Dumitrescu A. L., El-Aleem S. A., Morales-Aza B., Donaldson L. F., A model of periodontitis in the rat: effect of lipopolysaccharide on bone resorption, osteoclast activity, and local peptidergic innervation. Journal of Clinical Periodontology 2004 31 8 596 603 2-s2.0-1242313014 10.1111/j.1600-051X. 2004.00528.x (Pubitemid 39092219)
79. Bostanci N., Allaker R. P., Belibasakis G. N., Rangarajan M., Curtis M. A., Hughes F. J., McKay I. J., Porphyromonas gingivalis antagonises Campylobacter rectus induced cytokine production by human monocytes. Cytokine 2007 39 2 147 156 2-s2.0-34848890265 10.1016/j.cyto.2007.07.002 (Pubitemid 47513838)
80. Zou W., Bar-Shavit Z., Dual modulation of osteoclast differentiation by lipopolysaccharide. Journal of Bone and Mineral Research 2002 17 7 1211 1218 2-s2.0-0035991250 (Pubitemid 34680497)
81. Garlet G. P., Cardoso C. R., Silva T. A., Ferreira B. R., Ávila-Campos M. J., Cunha F. Q., Silva J. S., Cytokine pattern determines the progression of experimental periodontal disease induced by Actinobacillus actinomycetemcomitans through the modulation of MMPs, RANKL, and their physiological inhibitors. Oral Microbiology and Immunology 2006 21 1 12 20 2-s2.0-33645077356 10.1111/j.1399-302X.2005.00245.x
82. Mörmann M., Thederan M., Nackchbandi I., Giese T., Wagner C., Hänsch G. M., Lipopolysaccharides (LPS) induce the differentiation of human monocytes to osteoclasts in a tumour necrosis factor (TNF) α -dependent manner: a link between infection and pathological bone resorption. Molecular Immunology 2008 45 12 3330 3337 2-s2.0-44749086080 10.1016/j.molimm.2008.04.022
83. Kimura K., Kitaura H., Fujii T., Hakami Z. W., Takano-Yamamoto T., Anti-c-Fms antibody inhibits lipopolysaccharide-induced osteoclastogenesis in vivo. FEMS Immunology & Medical Microbiology 2012 64 2 219 227 10.1111/j.1574-695X.2011.00888.x